Leerink Swann`s Partnering & Acquisitions for Commercial Stage Biopharmaceuticals Investment Analysis Now Available

BOSTON--(Business Wire)--
Leerink Swann, the leading healthcare-focused investment banking firm, today
announced the availability of a new investment analysis focused on partnering
and acquisitions, or P&A, in the biopharmaceuticals industry.

The analysis, "Partnering and Acquisitions for Commercial-Stage
Biopharmaceuticals," is authored by several members of Leerink Swann`s Equity
Research team: Seamus Fernandez (major pharmaceuticals), Gary Nachman (specialty
pharmaceuticals), Eric Varma, MD (biotechnology) and John L. Sullivan, CFA,
director of equity research and healthcare strategist. It is the second
installment focused on the P&A landscape.

The firm`s first P&A report, published March 4, 2009, highlighted
development-stage biopharmaceuticals, and this report extends the analysis to
commercial-stage companies.

Since its release, the initial P&A "Top Ten" portfolio has significantly
outperformed a number of key healthcare indices. From March 4 through June 17,
2009, the P&A "Top Ten" portfolio rose 57.7% compared to 13.0% for the S&P 500
HC index (44.7% alpha) and 26.7% for the Russell 2000 HC index (31% alpha). The
equal-weighted portfolio consisted of ALXN, BIOD, CGRB, CRME, ELN, ISPH, JAV,
OREX, SVNT and SCMP.

Some of the trends and analysis addressed in the new report include:

* P&A will remain active through the remainder of 2009 and into 2010.
* Demand-side - Large- and mid-cap pharmaceutical companies with substantial
portfolio gaps, but a surplus of cash, have a more intense focus on business
development.
* Supply-side - Biopharmaceutical companies that are strategically attractive
but trading at historically low valuations.
* New Top Ten List: Released today.

Accredited media interested in access to the report should contact Risa Burgess
or Justin Drake at Schwartz Communications at leerink@schwartz-pr.com or
781-684-0770.

About Leerink Swann

Leerink Swann is a healthcare-focused investment banking firm that provides
equity research, corporate finance, strategic advisory and asset management
services for institutional, life sciences and high-net-worth clients. Every year
since 2001, Institutional Investor has named Leerink Swann "Best of the
Boutiques" in several healthcare categories. Through its MEDACorp division,
Leerink Swann provides biomedical-consulting services to the institutional
investment community. With an internal team of experts and a dedicated external
network of academic and community healthcare professionals, MEDACorp assesses
the viability of cutting-edge medical technologies, thus giving decision makers
the information they need to perform. Leerink Swann is a member of FINRA/SIPC.
For more information, visit www.leerink.com.

Schwartz Communications
Risa Burgess or Justin Drake, 781-684-0770
Leerink@schwartz-pr.com

Copyright Business Wire 2009